Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single-institution phase II trial of oxaliplatin, 5-fluorouracil, leucovorin [folinic acid] and bevacizumab (FOLFOX-B) for initially unresectable colorectal liver metastases: downstaging followed by hepatic resection.

Next Previous
X
Search
Trial Profile

Single-institution phase II trial of oxaliplatin, 5-fluorouracil, leucovorin [folinic acid] and bevacizumab (FOLFOX-B) for initially unresectable colorectal liver metastases: downstaging followed by hepatic resection.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary)
  • Indications Colorectal cancer; Liver metastases
  • Focus Therapeutic Use

    • Most Recent Events

    • 31 Jul 2012 Actual end date added as reported by ClinicalTrials.gov record.
    • 31 Jul 2012 Company changed from Sanofi-Synthelabo to Sanofi as reported by ClinicalTrials.gov record.
    • 14 Aug 2009 Actual patient number (2) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top